Prediction of Hepatic Metabolic Clearance
暂无分享,去创建一个
T Lavé | J Zuegge | G. Schneider | T. Lavé | G Schneider | J. Zuegge | P. Coassolo | P Coassolo
[1] J B Houston,et al. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[2] I. Helland. Partial least squares regression and statistical models , 1990 .
[3] A. A. Mullin,et al. Principles of neurodynamics , 1962 .
[4] D J Rance,et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.
[5] D. Campbell. Can Allometric Interspecies Scaling be Used to Predict Human Kinetics? , 1994 .
[6] R. Obach,et al. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[7] H Boxenbaum,et al. First‐Time‐in‐Human Dose Selection: Allometric Thoughts and Perspectives , 1995, Journal of clinical pharmacology.
[8] H Boxenbaum,et al. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. , 1984, Drug metabolism reviews.
[9] A. Höskuldsson. PLS regression methods , 1988 .
[10] R C Chou,et al. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. , 1997, Journal of pharmaceutical sciences.
[11] Y. Sugiyama,et al. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. , 1997, The Journal of pharmacology and experimental therapeutics.
[12] L. Gleser. Measurement, Regression, and Calibration , 1996 .
[13] J V Gobburu,et al. Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis. , 1996, Journal of pharmaceutical sciences.
[14] Y. Sugiyama,et al. Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. , 1997, The Journal of pharmacology and experimental therapeutics.
[15] Brian D. Ripley,et al. Pattern Recognition and Neural Networks , 1996 .
[16] A. Polak,et al. Combination therapy in systemic mycosis. , 1990, Journal of chemotherapy.
[17] P. Garthwaite. An Interpretation of Partial Least Squares , 1994 .
[18] Christopher M. Bishop,et al. Neural networks for pattern recognition , 1995 .
[19] Malcolm Rowland,et al. Clinical pharmacokinetics : concepts and applications , 1989 .
[20] T Lavé,et al. Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. , 1999, Journal of medicinal chemistry.
[21] T Lavé,et al. Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations , 1999, Clinical pharmacokinetics.
[22] R. Palmer,et al. Introduction to the theory of neural computation , 1994, The advanced book program.
[23] T Iwatsubo,et al. PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.
[24] M. Bayliss,et al. Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[25] G Reibnegger,et al. Neural networks as a tool for utilizing laboratory information: comparison with linear discriminant analysis and with classification and regression trees. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[26] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[27] D. Cross,et al. A COMMENTARY ON THE USE OF HEPATOCYTES IN DRUG METABOLISM STUDIES DURING DRUG DISCOVERY AND DEVELOPMENT* , 2000, Drug metabolism reviews.
[28] J B Houston,et al. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.
[29] T. Izumi,et al. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. , 1996, The Journal of pharmacology and experimental therapeutics.
[30] Y. Sugiyama,et al. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.
[31] R. Erb,et al. The Backpropagation Neural Network — A Bayesian Classifier , 1995, Clinical pharmacokinetics.
[32] Sam Kash Kachigan. Multivariate statistical analysis: A conceptual introduction , 1982 .
[33] G Schneider,et al. Artificial neural networks for computer-based molecular design. , 1998, Progress in biophysics and molecular biology.
[34] T Ishizaki,et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.
[35] John H. Mathews,et al. Numerical Methods For Mathematics, Science, and Engineering , 1987 .
[36] J. Mordenti,et al. Man versus beast: pharmacokinetic scaling in mammals. , 1986, Journal of pharmaceutical sciences.
[37] D. Jaeck,et al. Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.